Halozyme Therapeutics, a pioneer in drug delivery technologies, has announced a significant global exclusive partnership and license agreement with Vertex…
Read More
US Imposes 100% Tariff on Branded Pharmaceuticals, Sparking Industry Concerns and Geopolitical Debate
The pharmaceutical industry is bracing for significant disruption following the US administration’s recent decision to implement a 100% tariff on…
Read More
Sidewinder Therapeutics Secures $137 Million in Series B Financing to Advance Bispecific Antibody-Drug Conjugate Pipeline
Sidewinder Therapeutics has announced the successful closure of a substantial $137 million Series B financing round, a significant development signaling…
Read More
RoosterBio and MineBio Forge Exclusive Partnership to Accelerate MSC and Exosome Therapies in China
RoosterBio, a prominent innovator in the field of mesenchymal stem cell (MSC) and exosome bioprocessing, has announced an exclusive distributor…
Read More
The Hyper-Connected Hospital: Bridging the Gap Between Digital Ambition and Network Readiness
The healthcare landscape is undergoing a profound metamorphosis, transforming hospitals into hyper-connected environments where artificial intelligence applications, remote patient monitoring,…
Read More
US Import Tariffs Fail to Deter Biopharma Giants as European Contract Manufacturing Surges for FDA-Approved Drugs
The biopharmaceutical industry is demonstrating a significant and counterintuitive trend in 2025, with companies increasingly channeling investments into European-based contract…
Read More
Gilead Acquires Antibody-Drug Conjugate Pioneer Tubulis for Up to $5 Billion, Bolstering Oncology Pipeline
Sixteen months after forging a strategic collaboration, Gilead Sciences has announced its definitive agreement to acquire German biotechnology firm Tubulis,…
Read More
Pharma 50 2026: The top spot in pharma rarely lasts. Lilly is betting it can change that.
Eli Lilly has ascended to the pinnacle of the pharmaceutical industry, claiming the top spot on the prestigious Pharma 50…
Read More
Apnimed Secures Up to $150 Million in Credit Facility to Fuel Potential US Launch of Obstructive Sleep Apnea Therapy AD109
Boston, MA – – Apnimed, a clinical-stage biopharmaceutical company focused on developing novel therapies for sleep-related breathing disorders, has announced…
Read More
European Commission Approves Keytruda Combination Therapy for PD-L1-Positive Platinum-Resistant Ovarian Cancer
The European Commission (EC) has granted approval for Keytruda (pembrolizumab) in combination with paclitaxel, with or without bevacizumab, as a…
Read More
